<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276185</url>
  </required_header>
  <id_info>
    <org_study_id>CHU63-0003</org_study_id>
    <nct_id>NCT00276185</nct_id>
  </id_info>
  <brief_title>HEMITOX : Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke</brief_title>
  <official_title>Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>J. Rebeyrol Hospital in Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center of Physical Medicine and Rehabilitation (Notre Dame de Lourdes Center in Rennes)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint Jacques Hospital in Nantes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Régional de Département de médecine physique et réadaptation CHU-C3RF in Angers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Botulinum toxin produced beneficial effects in spasticity in the hemiplegic upper limb. This
      study will test if botulinum toxin injections at earlier phases (&lt;or = 3 months) in
      spasticity improve functional and motor tests compared with late injections (&gt;or = 6 months).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2005</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Deficiency, incapacity, handicap : Frenchay Arm test(post stroke arm function); Enjalbert test;</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Box and blocks test</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Enjalbert test</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Ashworth scale (upper limb)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Independence Measure</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Fugl-Meyer upper limb test</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>36-Item Short Form (SF-36) quality of life</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Range of pain</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual functional kinesitherapy</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hemiplegia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Time delay treatment of botulinum toxin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum age 18

          -  Spastic hemiplegia after ischemic stroke (carotid occlusion) within the past 3 months.

          -  Antispasticity medication stabilized for the last 30 days

          -  Severe cognitive impairment such that patient is unable to provide scale assessment.

          -  Significant spasticity impeding improvement by re-education for 2 months or less

          -  Lack of muscular retraction defined by a minimal range of articular motion as :

               -  finger : complete extension and rolling up

               -  wrist : extension 40°/flexion : 45°

               -  elbow : extension - 10°/flexion : 120°

               -  shoulder : Enjalbert score 2 or more

          -  Antagonist muscles (to spasticity) activity score 1 or more

          -  Social Security benefits

        Exclusion Criteria:

          -  Ischemic stroke thought to be due to basilar or vertebral vessel occlusion

          -  Known motor neuron or neuromuscular junction disease, disorders in which pain limits
             the ability to inject muscles (algodystrophy)

          -  Absence of mobility in proximal part of upper limb that does not predict a functional
             gain

          -  Minor stroke with non-disabling deficit or rapidly improving motor symptoms

          -  other serious illness, e.g. severe hepatic, cardiac, or renal failure ; acute
             myocardial infarction ; or a complex disease that may confound treatment assessment

          -  Treatment of spasticity by previous administration of botulinum toxin, if known

          -  Known allergy to botulinum toxin

          -  Currently participating in other research studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Durif</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franck Durif</last_name>
    <phone>(33) 04 73 750 750</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Durif</last_name>
      <phone>(33) 04 73 750 750</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Wissel J, Müller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage. 2000 Jul;20(1):44-9.</citation>
    <PMID>10946168</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>January 18, 2011</last_update_submitted>
  <last_update_submitted_qc>January 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pr Franck DURIF</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>spasticity ;</keyword>
  <keyword>Botulinum toxin ;</keyword>
  <keyword>Upper limb ;</keyword>
  <keyword>motor function.</keyword>
  <keyword>spastic hemiplegia after stoke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Hemiplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

